About Pluri
Pluri is a company based in Haifa (Israel) founded in 2003. The company has 118 employees as of June 30, 2024. Pluri has completed 1 acquisition, including Kokomodo. Pluri offers products and services including 3D Cell Expansion Platform, PLURIHEALTH, PLURIFOOD, PLURICDMO, and PLURIAGTECH. Pluri operates in a competitive market with competitors including Celloid, Mo:re, AIM Biotech, The Well Bioscience and S-BIO, among others.
- Headquarter Haifa, Israel
- Employees 118 as on 30 Jun, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pluri Inc.
-
Annual Revenue
$1.34 M (USD)309.82as on Jun 30, 2025
-
Net Profit
-$22.58 M (USD)-8.11as on Jun 30, 2025
-
EBITDA
-$21.86 M (USD)0.21as on Jun 30, 2025
-
Latest Funding Round
$2.5 M (USD), Post-IPO
Mar 26, 2026
-
Investors
European Union
& 3 more
-
Employee Count
118
as on Jun 30, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pluri
Pluri is a publicly listed company on the NASDAQ with ticker symbol PLUR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Pluri
Pluri offers a comprehensive portfolio of products and services, including 3D Cell Expansion Platform, PLURIHEALTH, PLURIFOOD, PLURICDMO, and PLURIAGTECH.
Platform for efficient growth of various cell types.
System for medical applications using cell expansion technology.
Technology for producing cultivated meat products.
Virtual platform offering cell-based services.
Platform for cell-based coffee and agricultural innovations.
People of Pluri
Unlock access to complete
Funding Insights of Pluri
Investors in Pluri
Pluri has secured backing from 4 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include European Union, Merchant Adventure Investment Advisors and Alejandro Weinstein.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Offers wealth management, investment advisory, and brokerage services in the U.S.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Pluri
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pluri
Pluri has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Kokomodo.
Investment portfolio details for Pluri
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cacao production is managed by Kokomodo in Rehovot, Israel.
|
Locked | Locked | 2024 | Locked |
Complete acquisition details for Pluri
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Pluri
Detailed financials for Pluri
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pluri Comparisons
Peer comparison for Pluri
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pluri
Pluri operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celloid, Mo:re, AIM Biotech, The Well Bioscience and S-BIO, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
3D cell culture solutions for drug development are provided.
|
|
| Locked | Locked | Locked |
3D cell culture robots are developed for medical research applications.
|
|
| Locked | Locked | Locked |
Microfluidic 3D cell culture systems are developed and manufactured.
|
|
| Locked | Locked | Locked |
Develops xeno-free hydrogels for 3D cell culture and personalized medicine applications.
|
|
| Locked | Locked | Locked |
Glycan analysis services and kits are offered by S-BIO.
|
Detailed competitors of Pluri
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pluri
Complete news archive for Pluri
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pluri
Pluri was founded in 2003 and raised its 1st funding round 14 years after it was founded.
Pluri is headquartered in Haifa, Israel. It is registered at Haifa, Haifa District, Israel.
Yaky Yanay is the current CEO of Pluri.
As of Jun 30, 2024, the latest employee count at Pluri is 118.
Annual revenue of Pluri is $1.34M as on Jun 30, 2025.
Founded in 2003 and based in Haifa, Israel, the company focuses on biotechnology through its platform for 3D cell expansion systems. Novel cell-based solutions are advanced for applications in medicine, climate change mitigation, pharmaceuticals, food technology, agriculture technology, and biologics production. Operations emphasize innovation in cell technologies to support diverse sectors.
Pluri's top competitors include Mo:re, Celloid and ExCel Matrix Biological Devices.
Pluri offers 3D Cell Expansion Platform, PLURIHEALTH, PLURIFOOD, PLURICDMO, and PLURIAGTECH.
Yes, Pluri is publicly traded on NASDAQ under the ticker symbol PLUR.
Pluri has made 1 acquisition, including Kokomodo.
Pluri has 4 investors. Key investors include European Union, Merchant Adventure Investment Advisors, Alejandro Weinstein, and Alliance Global Partners.
The ticker symbol of Pluri is PLUR on NASDAQ.